ARGENX SE: 2025 Annual Report (Form 20-F) Summary
Business Context and Reporting Period
Company: ARGENX SE (Netherlands)
Reporting Period: Fiscal year ended December 31, 2025
Core Business: Biopharmaceutical company focused on immunology, primarily commercializing VYVGART (efgartigimod alfa-fcab) for generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), and immune thrombocytopenia (ITP in Japan).
Key Milestone: VYVGART surpassed $1 billion in product net sales in a single quarter for the first time (Q3 2025). The company reached over 19,000 patients globally across three indications.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 ($ millions) | 2024 ($ millions) | Change |
|---|---|---|---|
| Product Net Sales | 4,151 | 2,186 | +90% |
| Operating Profit | 1,054 | (22) Loss | Turnaround to Profit |
| Net Profit | 1,292 | 833 | +55% |
| Diluted EPS | $19.57 | $12.78 | +53% |
| R&D Expenses | 1,364 | 983 | +39% |
| SG&A Expenses | 1,367 | 1,055 | +30% |
| Cash & Cash Equivalents | 3,491 | 1,500 | +133% |
| Total Assets | 8,683 | 6,203 | +40% |
Note: The company recorded its second consecutive year of profitability. The significant increase in cash is driven by positive operating cash flows and a shift in classification of financial assets.
Material Changes vs. Prior Period
- Revenue Growth: Product net sales nearly doubled, driven by global commercialization of VYVGART and the launch of the pre-filled syringe (PFS) formulation in the U.S., EU, and Japan.
- Profitability: Transitioned from a slight operating loss in 2024 to an operating profit of $1.05 billion in 2025. Net profit increased by 55%.
- Expense Increases: R&D expenses rose 39% due to increased personnel and external costs for advancing the pipeline (efgartigimod, empasiprubart, adimanebart). SG&A increased 30% due to scaling commercial operations and marketing.
- Balance Sheet: Cash and cash equivalents increased by $2.0 billion year-over-year. Total equity grew to $7.3 billion.
Guidance, Outlook, and Management Commentary
- Vision 2030: Strategic goal to treat 50,000 patients globally, secure 10 labeled indications, and advance five pipeline candidates into Phase 3 by 2030.
- 2026 Outlook: Focus on three priorities: expanding VYVGART adoption, advancing FcRn medicines, and delivering next-wave immunology innovation (empasiprubart).
- Clinical Readouts Expected in 2026:
- Q1: Ocular MG (ADAPT OCULUS)
- Q3: Myositis (ALKIVIA)
- Q4: MMN (EMPASSION) and Primary ITP (ADVANCE-NEXT)
- Leadership Transition: Current CEO Tim Van Hauwermeiren will transition to Non-Executive Chairperson. Current COO Karen Massey will become CEO, subject to shareholder approval at the 2026 General Meeting.
- Risks: Key risks include regulatory approval timelines, pricing pressures (IRA, MFN pricing), biosimilar competition (exclusivity expected to expire 2032-2033), and reliance on third-party manufacturers.
Investor Verification Checklist
- Regulatory Approvals: Verify the PDUFA date for Seronegative gMG (expected May 10, 2026) and the status of CIDP approvals in the EU and UK.
- Revenue Concentration: Confirm the concentration of sales in the U.S. (approx. 85% of total sales) and the impact of four major U.S. customers representing ~78% of sales.
- Deferred Tax Assets: Review the recognition of $1.3 billion in deferred tax assets, which relies on the probability of future taxable profits.
- Manufacturing Capacity: Assess the capacity and reliability of third-party manufacturers (Lonza, Fujifilm) given the $1.3 billion in outstanding commercial supply commitments.
- Leadership Transition: Monitor the execution of the CEO transition and its impact on strategic continuity.